OBJECTIVE: To determine the mechanisms of amelioration of collagen-induced arthritis (CIA) in DBA/1J mice by inhibition of complement activation. METHODS: Mice received 2 intradermal injections of bovine type II collagen (CII), on days 0 and 21. From day 21 (immediately after the second injection of CII) through day 35, mice received intraperitoneal injections of either phosphate buffered saline (PBS), a monoclonal mouse antibody to murine C5 (anti-C5 antibody), or the C3 convertase inhibitor Crry-Ig. RESULTS: On days 30 and 32, the clinical disease activity score was lower in mice treated with anti-C5 antibody than in those treated with Crry-Ig. Histopathologic evidence of joint damage was 75% lower in the mice treated with anti-C5 antibody than in those treated with either PBS or Crry-Ig. Spleen cells from mice receiving either form of complement inhibition exhibited decreased CII-stimulated proliferation, whereas increased proliferative responses were exhibited by lymph node cells from mice treated with Crry-Ig. Treatment with anti-C5 antibody decreased production of IgG1 anticollagen antibody, while production of IgG2a antibody was inhibited by both complement inhibitory treatments. CII-stimulated spleen cells from anti-C5-treated mice produced lower levels of tumor necrosis factor alpha (TNFalpha) and interleukin-10 (IL-10) compared with those from mice treated with Crry-Ig. Lower steady-state messenger RNA (mRNA) levels for TNFalpha, interferon-gamma (IFNgamma), IL-18, and IL-6 were observed in the joints of anti-C5-treated mice, and for IFNgamma and IL-6 in mice receiving Crry-Ig, all in comparison with PBS-treated mice. However, mRNA levels for IL-1beta and TNFalpha were lower in the joints after treatment with anti-C5 compared with Crry-Ig. CONCLUSION: These results indicate that inhibition of complement in CIA leads to decreased production of IgG2a antibody and suppressed CII-induced spleen cell proliferation. The greater inhibitory effects on CIA of anti-C5 antibody in comparison with Crry-Ig may be attributable primarily to decreased levels of IL-1beta and TNFalpha mRNA in the joints.
OBJECTIVE: To determine the mechanisms of amelioration of collagen-induced arthritis (CIA) in DBA/1J mice by inhibition of complement activation. METHODS:Mice received 2 intradermal injections of bovine type II collagen (CII), on days 0 and 21. From day 21 (immediately after the second injection of CII) through day 35, mice received intraperitoneal injections of either phosphate buffered saline (PBS), a monoclonal mouse antibody to murineC5 (anti-C5 antibody), or the C3 convertase inhibitor Crry-Ig. RESULTS: On days 30 and 32, the clinical disease activity score was lower in mice treated with anti-C5 antibody than in those treated with Crry-Ig. Histopathologic evidence of joint damage was 75% lower in the mice treated with anti-C5 antibody than in those treated with either PBS or Crry-Ig. Spleen cells from mice receiving either form of complement inhibition exhibited decreased CII-stimulated proliferation, whereas increased proliferative responses were exhibited by lymph node cells from mice treated with Crry-Ig. Treatment with anti-C5 antibody decreased production of IgG1 anticollagen antibody, while production of IgG2a antibody was inhibited by both complement inhibitory treatments. CII-stimulated spleen cells from anti-C5-treated mice produced lower levels of tumor necrosis factor alpha (TNFalpha) and interleukin-10 (IL-10) compared with those from mice treated with Crry-Ig. Lower steady-state messenger RNA (mRNA) levels for TNFalpha, interferon-gamma (IFNgamma), IL-18, and IL-6 were observed in the joints of anti-C5-treated mice, and for IFNgamma and IL-6 in mice receiving Crry-Ig, all in comparison with PBS-treated mice. However, mRNA levels for IL-1beta and TNFalpha were lower in the joints after treatment with anti-C5 compared with Crry-Ig. CONCLUSION: These results indicate that inhibition of complement in CIA leads to decreased production of IgG2a antibody and suppressed CII-induced spleen cell proliferation. The greater inhibitory effects on CIA of anti-C5 antibody in comparison with Crry-Ig may be attributable primarily to decreased levels of IL-1beta and TNFalpha mRNA in the joints.
Authors: Masha Fridkis-Hareli; Michael Storek; Eran Or; Richard Altman; Suresh Katti; Fang Sun; Tao Peng; Jeff Hunter; Krista Johnson; Yi Wang; Ante S Lundberg; Gaurav Mehta; Nirmal K Banda; V Michael Holers Journal: Mol Immunol Date: 2018-12-01 Impact factor: 4.407
Authors: Carl Atkinson; Fei Qiao; Xiaofeng Yang; Peng Zhu; Nicholas Reaves; Liudmila Kulik; Martin Goddard; V Michael Holers; Stephen Tomlinson Journal: Circulation Date: 2015-02-17 Impact factor: 29.690
Authors: Van C Willis; Alison M Gizinski; Nirmal K Banda; Corey P Causey; Bryan Knuckley; Kristen N Cordova; Yuan Luo; Brandt Levitt; Magdalena Glogowska; Piyanka Chandra; Liudmila Kulik; William H Robinson; William P Arend; Paul R Thompson; V Michael Holers Journal: J Immunol Date: 2011-02-23 Impact factor: 5.422
Authors: Widian K Jubair; Jason D Hendrickson; Erin L Severs; Hanna M Schulz; Sumitra Adhikari; Diana Ir; Jose D Pagan; Robert M Anthony; Charles E Robertson; Daniel N Frank; Nirmal K Banda; Kristine A Kuhn Journal: Arthritis Rheumatol Date: 2018-07-02 Impact factor: 10.995
Authors: Jason J Song; Inyong Hwang; Kyung H Cho; Michael A Garcia; Arthur J Kim; Tiffany H Wang; Tamsin M Lindstrom; Annette T Lee; Toshihiko Nishimura; Lei Zhao; John Morser; Michael Nesheim; Stuart B Goodman; David M Lee; S Louis Bridges; Peter K Gregersen; Lawrence L Leung; William H Robinson Journal: J Clin Invest Date: 2011-08-01 Impact factor: 14.808